The Mg2+-dependent salicylate synthase (MbtI) from Mycobacterium tuberculosis is a key enzyme involved in the biosynthesis of siderophores. Because iron is essential for the survival and pathogenicity of the microorganism, this protein constitutes an attractive target for antitubercular therapy, also considering the absence of homologous enzymes in mammals. An extension of the SAR of our furan-based candidates allowed us to disclose the most potent competitive inhibitor known to date (10, Ki = 4 μM), which also proved effective on mycobacterial cultures. By structural studies, we characterized its unexpected Mg2+-independent binding mode. We also investigated the role of the Mg2+ cofactor in catalysis, analyzing the first crystal structure of the MbtI-Mg2+-salicylate ternary complex. Overall, these results pave the way for the development of novel antituberculars through the rational design of improved MbtI inhibitors.

Shedding X-ray light on the role of magnesium in the activity of M. tuberculosis salicylate synthase (MbtI) for drug design / M. Mori, G. Stelitano, A. Gelain, E. Pini, L.R. Chiarelli, J.C. Sammartino, G. Poli, T. Tuccinardi, G. Beretta, A. Porta, M. Bellinzoni, S. Villa, F. Meneghetti. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 63:13(2020 Jul 09), pp. 7066-7080. [10.1021/acs.jmedchem.0c00373]

Shedding X-ray light on the role of magnesium in the activity of M. tuberculosis salicylate synthase (MbtI) for drug design

M. Mori
Co-primo
;
A. Gelain
Secondo
;
E. Pini;G. Beretta;S. Villa
Penultimo
;
F. Meneghetti
Ultimo
2020

Abstract

The Mg2+-dependent salicylate synthase (MbtI) from Mycobacterium tuberculosis is a key enzyme involved in the biosynthesis of siderophores. Because iron is essential for the survival and pathogenicity of the microorganism, this protein constitutes an attractive target for antitubercular therapy, also considering the absence of homologous enzymes in mammals. An extension of the SAR of our furan-based candidates allowed us to disclose the most potent competitive inhibitor known to date (10, Ki = 4 μM), which also proved effective on mycobacterial cultures. By structural studies, we characterized its unexpected Mg2+-independent binding mode. We also investigated the role of the Mg2+ cofactor in catalysis, analyzing the first crystal structure of the MbtI-Mg2+-salicylate ternary complex. Overall, these results pave the way for the development of novel antituberculars through the rational design of improved MbtI inhibitors.
Tuberculosis; magnesium; divalent cations; antitubercular agents; MST enzymes; catalytic mechanism; siderophores; X-ray crystal structures; mycobactins; MbtI conformations.
Settore CHIM/08 - Chimica Farmaceutica
9-lug-2020
25-giu-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
JMC 2020 Mori et al..pdf

Open Access dal 26/06/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.39 MB
Formato Adobe PDF
1.39 MB Adobe PDF Visualizza/Apri
Manuscript Mori et al._Revised .pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 1.62 MB
Formato Adobe PDF
1.62 MB Adobe PDF Visualizza/Apri
acs.jmedchem.0c00373.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 4.45 MB
Formato Adobe PDF
4.45 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/740759
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 19
social impact